Edgestream Partners L.P. Makes New Investment in Avantor, Inc. (NYSE:AVTR)

Edgestream Partners L.P. acquired a new stake in Avantor, Inc. (NYSE:AVTR) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 48,574 shares of the company’s stock, valued at approximately $1,242,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Fifth Third Bancorp increased its stake in shares of Avantor by 125.3% in the fourth quarter. Fifth Third Bancorp now owns 1,248 shares of the company’s stock valued at $28,000 after buying an additional 694 shares during the period. Livforsakringsbolaget Skandia Omsesidigt boosted its holdings in Avantor by 565.5% in the fourth quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,331 shares of the company’s stock valued at $30,000 after acquiring an additional 1,131 shares during the last quarter. Gladius Capital Management LP bought a new stake in Avantor in the fourth quarter valued at approximately $42,000. Montag A & Associates Inc. bought a new stake in Avantor in the fourth quarter valued at approximately $43,000. Finally, TFO Wealth Partners LLC boosted its holdings in Avantor by 203,100.0% in the fourth quarter. TFO Wealth Partners LLC now owns 2,032 shares of the company’s stock valued at $46,000 after acquiring an additional 2,031 shares during the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Robert W. Baird reduced their target price on Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a report on Monday, April 29th. Royal Bank of Canada upped their target price on Avantor from $30.00 to $31.00 and gave the company an “outperform” rating in a report on Monday, July 15th. Citigroup cut Avantor from a “buy” rating to a “neutral” rating and reduced their target price for the company from $30.00 to $23.00 in a report on Wednesday, July 10th. Evercore ISI reduced their target price on Avantor from $28.00 to $27.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. Finally, Deutsche Bank Aktiengesellschaft increased their price target on Avantor from $23.00 to $25.00 and gave the stock a “hold” rating in a report on Thursday, April 18th. Five equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, Avantor presently has a consensus rating of “Moderate Buy” and a consensus target price of $25.93.

Avantor Stock Up 1.9 %

Shares of NYSE:AVTR traded up $0.41 during trading on Tuesday, reaching $21.50. 3,031,352 shares of the stock were exchanged, compared to its average volume of 5,808,605. The company has a debt-to-equity ratio of 0.94, a current ratio of 1.61 and a quick ratio of 1.05. Avantor, Inc. has a 1-year low of $16.63 and a 1-year high of $26.16. The stock has a fifty day moving average of $22.56 and a two-hundred day moving average of $23.62. The firm has a market cap of $14.60 billion, a price-to-earnings ratio of 54.08, a price-to-earnings-growth ratio of 2.13 and a beta of 1.32.

Avantor (NYSE:AVTR) last issued its earnings results on Friday, April 26th. The company reported $0.22 earnings per share for the quarter, topping analysts’ consensus estimates of $0.20 by $0.02. Avantor had a return on equity of 13.01% and a net margin of 3.79%. The company had revenue of $1.68 billion for the quarter, compared to analyst estimates of $1.68 billion. During the same period in the prior year, the firm earned $0.29 earnings per share. Avantor’s revenue for the quarter was down 5.6% on a year-over-year basis. Research analysts anticipate that Avantor, Inc. will post 1.01 earnings per share for the current fiscal year.

Avantor Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.